FDA Review Backs Vytorin in Kidney Disease Patients - MedPage Today PDF Print
MedPage Today
The review also highlighted the greater benefit of the combination in patients not yet on dialysis, with a risk ratio for the primary outcome of 0.77 (95% CI 0.67 to 0.88) versus 0.94 (not significant) among dialysis patients. ...
FDA backs Merck cholesterol drug to lower heart problems in kidney disease

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.